CORONA Remedies LimitedCORONACorporate

Pharmaceuticals Latest results: Jun 2026 6 quarters of data

₹2,003.90

MCap ₹12,204 Cr · P/E 61.6

CORONA Remedies Limited — Stock analysis & AI research CORONA Remedies Limited — Multibagger AI analysis CORONA Remedies Limited — Seasonality — best & worst months CORONA Remedies Limited — Technical setup — score, trend, support & resistance CORONA Remedies Limited — Live exchange announcements

📋 High Interest Coverage Stocks 📋 Stocks With Strong Quarterly Results 📋 High Promoter Holding Stocks 📈 Unusual Volume Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹422 Cr

Sales · Jun 2026

+21.7% YoY

₹93 Cr

Operating Profit · Jun 2026

+33.0% YoY

22.0%

OPM % · Jun 2026

+8.9% YoY

₹60 Cr

Net Profit · Jun 2026

+30.7% YoY

₹9.83

EPS · Jun 2026

+29.5% YoY

📝 CORONA Remedies Limited — results explained

Quarter ended June 2026 (Q1 FY27)

CORONA Remedies Limited reported revenue of ₹422 crore for the quarter ended June 2026 (Q1 FY27), up 21.7% from ₹347 crore in the same quarter last year, and up 19.6% sequentially over the March 2026 quarter.

Net profit rose 30.7% year-on-year to ₹60 crore, from ₹46 crore. Earnings per share (EPS) came in at ₹9.83.

Operating profit stood at ₹93 crore — an operating margin (OPM) of 22.0%, compared with 20.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, CORONA Remedies Limited posted revenue of ₹1,403 crore, with a net profit of ₹184 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,479 crore with a net profit of ₹198 crore.

Valuation snapshot

At the current price of ₹2,003.90, CORONA has a market capitalisation of ₹12,204 crore and a trailing P/E of about 61.6.

Shareholding pattern

As of Sep 2026, promoters held 69.00%, foreign institutional investors (FIIs) 4.21%, domestic institutional investors (DIIs) 16.45%, public shareholders 10.34% of CORONA Remedies Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹12,204 Cr

Current Price ?

₹2,003.9

P/E ?

61.59above ind

Industry P/E ?

22.40

P/B ?

N/A

P/S ?

8.25

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

1.6%

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

₹1,479 Cr

OPM ?

21.4%

Profit after tax (TTM) ?

₹198 Cr

EPS (TTM) ?

₹32.54

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹422 Cr

PAT — latest qtr ?

₹60 Cr

YoY qtr sales growth ?

21.7%

YoY qtr profit growth ?

30.7%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

N/A

Debt to Equity ?

N/A

Interest Coverage ?

34.7

Current Ratio ?

N/A

Ownership

Promoter holding ?

69.00%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-2.8%

Return 6 months ?

23.7%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	294	347	361	342	353	422	+21.7%	+19.6%
Operating Profit	54	70	78	83	62	93	+33.0%	+50.2%
Other Income	1	2	2	-17	4	3	+57.5%	-23.4%
Interest	2	2	2	2	1	3	+34.5%	+94.9%
Depreciation	10	9	9	9	10	13	+47.1%	+28.7%
Profit Before Tax	43	61	70	55	54	80	+31.7%	+47.5%
Net Profit	31	46	52	41	45	60	+30.7%	+33.4%
EPS	5.12	7.59	8.53	6.74	7.37	9.83	+29.5%	+33.4%
OPM %	18.4%	20.2%	21.6%	24.3%	17.6%	22.0%	+8.9%	+25.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	Prev FY	FY26	TTM	YoY %
Sales	—	₹1,403 Cr	₹1,479 Cr	—
Operating Profit	—	₹293 Cr	₹316 Cr	—
OPM %	—	20.88%	21.38%	—
NPM %	—	13.12%	13.40%	—
Other Income	—	₹-9 Cr	₹-8 Cr	—
Depreciation	—	₹37 Cr	₹42 Cr	—
Interest	—	₹7 Cr	₹8 Cr	—
EBIT	—	₹256 Cr	₹275 Cr	—
PBT	—	₹240 Cr	₹260 Cr	—
Tax	—	₹9 Cr	₹30 Cr	—
Net Profit	—	₹184 Cr	₹198 Cr	—
EPS	—	₹30.23	₹32.47	—
Material Cost	—	₹74 Cr	₹164 Cr	—
Employee Cost	—	₹107 Cr	₹229 Cr	—
Extraordinary Items	—	—	—	—

👥 Shareholding (latest 1 periods)

Metric	Sep 2026	% Chg
Promoters	69.00%	—
FIIs	4.21%	—
DIIs	16.45%	—
Public	10.34%	—
No. of Shareholders	21,098	—

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	CORONA CORONA Remedies	₹2,037.10	—	62.6	1,479	198	21.4%	13.4%	—	—	21.7%	30.7%

❓ Frequently asked questions

What was CORONA Remedies Limited's revenue in Q1 FY27?

What was CORONA Remedies Limited's net profit in Q1 FY27?